The company has also laid off 39% of its staff as it discontinued the development of SPR720 for non-tuberculous mycobacterial ...

Following disappointing results for an antibiotic candidate whose development program is now being suspended, Spero ...

Phase 2a proof-of-concept study of SPR720 for the treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) did not meet its primary ...

Stock analysts at HC Wainwright raised their Q3 2024 earnings per share (EPS) estimates for shares of Spero Therapeutics in a ...

Spero Therapeutics (SPRO) stock tumbled 20% post-market after the company announced it was cutting its workforce by 39% in the wake of a failed Phase 2 study for its drug SPR720.

Spero Therapeutics Inc. investors can’t proceed with a proposed class action over the drugmaker’s optimistic statements about ...

Spero Therapeutics (SPRO) announced that a planned interim analysis of the Phase 2a proof-of-concept study of SPR720 for the treatment of ...

Not much went right for Spero Therapeutics’ SPR720 in its phase 2a trial. | Not much went right for Spero Therapeutics’ SPR720 in its phase 2a trial. An interim analysis revealed a double blow to the ...

周一，H.C. Wainwright调整了对Spero Therapeutics (NASDAQ:SPRO)的展望，将目标价从之前的$7下调至$5，同时维持对该股的买入评级。这一修订是在Spero Therapeutics上周宣布其SPR720治疗非结核分枝杆菌肺病 (NTM-PD)的二期a概念验证研究的中期结果之后做出的。

马萨诸塞州剑桥 - Spero Therapeutics, Inc. (NASDAQ:SPRO)宣布暂停其SPR720开发项目，此前一项中期分析显示，该药物在非结核分枝杆菌肺病 (NTM-PD)治疗的2a期概念验证研究中未能达到主要终点。这项包含16名患者数据的分析显示，与安慰剂相比差异不足，并存在潜在的剂量限制性安全问题，包括可逆的3级肝毒性病例。